Compound research

TB-500 (Thymosin Beta-4 Fragment): A Research Overview

Aminent Labs Research·Updated July 2026·For Research Use Only·6 min read

TB-500 is a synthetic peptide corresponding to the actin-binding region of the naturally occurring protein Thymosin Beta-4 (TB4). It is the subject of ongoing laboratory investigation into actin regulation, cell migration and tissue-repair biology in cell-culture and animal-model systems. This page summarizes the peptide's biochemistry and its documented contexts of preclinical study. The information here is provided strictly for research and educational purposes; TB-500 is a research-use-only (RUO) material and is not a drug, supplement, or article intended for human or veterinary use.

What is TB-500?

TB-500 is a synthetic peptide that corresponds to a fragment of Thymosin Beta-4 (TB4), an endogenous, 43-amino-acid protein (molecular weight approximately 4.9 kDa) found intracellularly in nearly all mammalian cell types. TB4 is described in the literature as one of the most abundant intracellular actin-sequestering proteins.

TB-500 is not the full-length protein. It is a short synthetic peptide built around the central actin-binding motif of TB4, historically designated the LKKTET sequence. The most commonly referenced chemical definition of TB-500 is the N-terminally acetylated heptapeptide Ac-LKKTETQ (residues 17-23 of TB4), with a molecular weight near 889 g/mol. It is important to distinguish TB-500 (a short synthetic fragment) from full-length recombinant or synthetic TB4; the two are chemically distinct, and much of the primary mechanistic literature refers to the full-length protein.

Mechanisms studied in research

The mechanism most frequently investigated in the peptide literature is G-actin (monomeric actin) sequestration. In cell and biochemical models, Thymosin Beta-4 has been studied as a regulator of the pool of monomeric actin available for filament polymerization, thereby influencing the balance between actin assembly and disassembly. Because actin dynamics underlie cytoskeletal remodeling, researchers have used TB4 and its fragments as tools to probe how cytoskeletal reorganization is regulated.

Downstream of this cytoskeletal role, preclinical studies have examined associations with cell migration and angiogenesis. In in-vitro endothelial and cell-culture systems, investigators have reported observations consistent with modulation of the actin-driven reorganization involved in cell motility and in the formation of vascular-like structures. These are reported as findings within specific experimental systems and should be read as hedged, model-dependent research observations rather than established or generalizable conclusions.

Areas of preclinical investigation

Published research involving Thymosin Beta-4 and TB-500-type fragments has been carried out in in-vitro and animal-model contexts. Reported areas of preclinical investigation in the literature include:

Cell-migration research -- cell-culture assays examining actin-dependent motility.
Angiogenesis models -- in-vitro and animal systems studying the formation of vascular structures.
Tissue-repair research models -- animal studies spanning skeletal-muscle injury, tendon and ligament tissue, cardiac tissue, neurological tissue, and ocular research such as corneal wound-healing models.

All of the above describe research conducted in laboratory or animal-model systems. None of these constitute evidence of safety or efficacy in humans, and nothing here should be interpreted as a therapeutic or performance claim.

Regulated status in sport: TB-500 is prohibited in sport by the World Anti-Doping Agency (WADA). It falls under Section S2 of the WADA Prohibited List and is prohibited at all times, both in and out of competition. This status is noted here as a factual regulatory point and does not imply any endorsement of use by humans or athletes.

Stability, handling & storage

Research-grade peptides such as TB-500 are typically supplied as a lyophilized (freeze-dried) powder, a form chosen for stability during storage and shipping. General laboratory practice is to store lyophilized peptide sealed and protected from moisture and light; short-term storage is often at refrigerated temperatures (2-8 C), while long-term storage of the dry powder is commonly at -20 C or colder. Repeated freeze-thaw cycles are generally minimized, and aliquoting is a common practice to reduce them.

For in-vitro experimental work, lyophilized peptides are reconstituted in an appropriate laboratory solvent selected for the assay. Reconstituted peptide in solution is typically less stable than the dry powder and is handled accordingly. These are general laboratory-handling considerations for characterized research materials and are not instructions for preparing any substance for administration to humans or animals.

How research-grade peptides are characterized

The analytical value of a research peptide depends on documented identity and purity. Standard characterization methods for a compound like TB-500 include:

HPLC -- used to assess chromatographic purity, typically reported as an area-percent figure.
Mass spectrometry -- used to confirm molecular identity by verifying that the observed mass matches the expected peptide mass (approximately 889 Da for Ac-LKKTETQ).
Certificate of Analysis (COA) -- a document reporting purity, identity, and often net peptide content for a specific lot.

Net-content information matters because a lyophilized vial's total mass can include residual counter-ions, water, and salts; the peptide fraction is what is relevant for quantitative in-vitro work. Reviewing lot-specific HPLC and mass-spec data, along with the COA, is standard practice when evaluating a research-grade peptide for laboratory use.

How research-grade TB-500 is synthesized

At seven residues, TB-500 is a short peptide by synthetic standards and is assembled by solid-phase peptide synthesis (SPPS): the chain is built stepwise on a resin support, then cleaved, deprotected, and purified — typically by preparative reverse-phase HPLC. Short sequences of this length generally couple cleanly, which is one reason well-made material of this compound can reach high area-percent purity.

One synthetic detail is worth understanding because it directly affects identity confirmation. The N-terminus is acetylated, and that acetyl group is part of the defined molecule rather than an optional extra. Acetylation caps the free N-terminal amine, adding roughly 42 Da relative to the unacetylated heptapeptide — which is what the Ac- prefix in the name records, one of the conventions covered in Peptide Nomenclature and Sequence Notation. A lot that was not acetylated — or was only partially acetylated — is therefore a different molecule with a measurably different mass, and mass spectrometry is exactly the test that distinguishes them. The general impurity families that arise from incomplete coupling or capping are described in Peptide Impurities Explained.

Reading a TB-500 certificate of analysis

What a certificate should establish for this compound specifically:

Identity by mass. The observed mass should match the acetylated heptapeptide Ac-LKKTETQ at approximately 889 g/mol. A result near 847 would indicate unacetylated material; a result in the kilodalton range would indicate something other than the fragment entirely. This single number is the most direct check that a vial contains the compound it claims.
Purity by HPLC. An area-percent figure at 220 nm, reported together with the method. Because the sequence is short and contains no strongly chromophoric residue, detection relies on the peptide bond itself rather than on aromatic absorbance — see HPLC vs mass spectrometry for why purity and identity are separate questions.
Net peptide content. Particularly consequential here. The sequence carries two lysine residues, and basic side chains readily associate with the acidic counter-ions left by reverse-phase purification — typically trifluoroacetate or acetate. A vial of this compound can therefore carry a meaningful counter-ion and water fraction, so gross powder mass overstates peptide mass. Net Peptide Content vs. Purity covers the correction.

Per-lot reports are published on the certificates of analysis page, and lot documentation accompanies the TB-500 listing. How to Read a Peptide COA walks through a certificate field by field.

Points of confusion in the literature

This compound attracts more naming confusion than most, and the distinctions are substantive rather than pedantic.

TB-500 is not Thymosin Beta-4. This is the single most consequential point. Thymosin Beta-4 is an endogenous 43-residue protein of roughly 4.9 kDa; TB-500 is a synthetic seven-residue fragment of roughly 889 g/mol corresponding to residues 17-23. The two differ by more than fivefold in mass. Vendor listings and even some secondary sources use the names interchangeably, and a certificate quoting a kilodalton-scale mass for a product sold as TB-500 is describing a different molecule. Any molar calculation that substitutes one mass for the other will be wrong by a large factor.

LKKTET versus LKKTETQ. Older literature often refers to the actin-binding motif as the hexapeptide LKKTET. The compound supplied as TB-500 is normally the acetylated heptapeptide Ac-LKKTETQ, which includes the terminal glutamine. When comparing a reported mass against a reference, confirm which of the two sequences — and whether the acetylated or free form — the reference describes.

Fragment activity is not parent-protein activity. Findings reported for full-length Thymosin Beta-4 in the preclinical literature describe the intact protein. They do not automatically transfer to the short fragment, and the two should be tracked separately when reading the research record.

Compounds studied alongside it. Parts of the preclinical connective-tissue literature discuss this fragment and BPC-157 in adjacent contexts, and the two are supplied together as a paired research vial. They are chemically unrelated, with different sequences and masses, and each requires its own identity and purity documentation.

FAQ

What is TB-500? TB-500 is a synthetic peptide corresponding to the actin-binding region of Thymosin Beta-4 (TB4), a naturally occurring 43-amino-acid protein. It is most commonly defined as the acetylated heptapeptide Ac-LKKTETQ (molecular weight ~889 g/mol). It is studied as a research-use-only material in in-vitro and preclinical animal systems, not as a product for human use.

Is TB-500 approved for any use? No. TB-500 is an unapproved research chemical. It is not a drug, dietary supplement, or approved therapeutic, and it has not been approved by the FDA or comparable authorities for human or veterinary use. It is offered strictly for research-use-only (RUO) laboratory purposes. It is also prohibited in sport at all times by the World Anti-Doping Agency under Section S2 of the Prohibited List.

How should TB-500 be stored? As a general laboratory practice for characterized research peptides, lyophilized TB-500 is kept sealed and protected from light and moisture -- refrigerated (2-8 C) for the short term and frozen (-20 C or colder) for long-term storage. Aliquoting is commonly used to limit repeated freeze-thaw cycles. These are general handling notes for laboratory materials, not preparation instructions for any use in humans or animals.

How is purity verified? Research-grade peptides are typically characterized by HPLC (to assess chromatographic purity), mass spectrometry (to confirm the expected molecular mass), and a lot-specific Certificate of Analysis (COA). Net peptide content is also relevant, since a lyophilized vial's total mass may include salts and residual water in addition to the peptide itself.

Is TB-500 the same as Thymosin Beta-4? No, and the difference is large. Thymosin Beta-4 is an endogenous 43-amino-acid protein with a molecular weight of roughly 4.9 kDa. TB-500 is a synthetic seven-residue fragment corresponding to residues 17-23 of that protein, supplied as the acetylated heptapeptide Ac-LKKTETQ with a molecular weight of approximately 889 g/mol. The names are often used interchangeably in vendor listings, but they denote different molecules, and a certificate reporting a kilodalton-scale mass for material sold as TB-500 does not describe the fragment.

Why does the acetyl group matter? Because it is part of the defined molecule and is what mass spectrometry checks. N-terminal acetylation caps the free amine and adds roughly 42 Da, so the acetylated heptapeptide lands near 889 g/mol while unacetylated material would appear near 847. Confirming which mass a lot actually shows is the most direct way to establish that the vial contains the intended compound.

References & further reading

Related research

BPC-157: A Research Overview→ Net Peptide Content vs. Purity→ How to Read a Peptide COA→

For Research Use Only. All Aminent Labs materials are intended solely for in-vitro research and laboratory use — not for human or veterinary use. View the product page, browse the catalog, or review certificates of analysis.